Cargando…
Triheptanoin – Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency
Mitochondrial malate dehydrogenase (MDH2) deficiency (MDH2D) is an ultra-rare disease with only three patients described in literature to date. MDH2D leads to an interruption of the tricarboxylic acid (TCA) cycle and malate-aspartate shuttle (MAS) and results in severe early onset encephalopathy. Af...
Autores principales: | Laemmle, Alexander, Steck, Andrea Lisa, Schaller, André, Kurth, Sandra, Perret Hoigné, Eveline, Felser, Andrea Deborah, Slavova, Nedelina, Salvisberg, Claudia, Atencio, Mariana, Mochel, Fanny, Nuoffer, Jean-Marc, Gautschi, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529553/ https://www.ncbi.nlm.nih.gov/pubmed/34712577 http://dx.doi.org/10.1016/j.ymgmr.2021.100814 |
Ejemplares similares
-
No effect of triheptanoin on exercise performance in McArdle disease
por: Madsen, Karen L., et al.
Publicado: (2019) -
Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: a sustained dramatic effect
por: Hainque, Elodie, et al.
Publicado: (2019) -
A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood
por: Hainque, Elodie, et al.
Publicado: (2017) -
Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020) -
Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency
por: Mochel, Fanny, et al.
Publicado: (2016)